New drug duo aims to shrink advanced kidney tumors
NCT ID NCT05256472
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This phase 2 trial is testing a new drug called cadonilimab (AK104), either alone or combined with axitinib, as a first treatment for advanced or metastatic kidney cancer. The study includes two parts: one testing different doses of cadonilimab alone in various kidney cancer types, and another testing the combination in clear cell kidney cancer. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cadonilimab (AK104) and axitinib
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced kidney cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early-phase trial with only 28 participants, so results may not apply to all patients. Side effects from immunotherapy and targeted therapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- IBR854 + Pazopanib for Advanced Kidney Cancer (NCT07087158)
- Tazemetostat Expanded Access for Solid Tumors NCT03874455
- Renal Ablation Outcomes Registry (ARMOR) NCT01888198
- LAYOVER Trial: Ablative Therapy for Oligo-Progre NCT06101290
- TRK-950 Combination Therapy for Advanced Solid T NCT03872947
- IMEPOCA Study: Nivolumab Fixed vs Weight-Based D NCT05380336
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China